Victorya
2021-09-30
Ok
Temasek-backed Covid-19 test provider Oxford Nanopore soars in London trading debut
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":865258718,"tweetId":"865258718","gmtCreate":1632991139349,"gmtModify":1632994775891,"author":{"id":4096091521769740,"authorId":4096091521769740,"authorIdStr":"4096091521769740","name":"Victorya","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/865258718","repostId":1104048333,"repostType":4,"repost":{"id":"1104048333","pubTimestamp":1632989880,"share":"https://www.laohu8.com/m/news/1104048333?lang=&edition=full","pubTime":"2021-09-30 16:18","market":"sg","language":"en","title":"Temasek-backed Covid-19 test provider Oxford Nanopore soars in London trading debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1104048333","media":"Bloomberg","summary":"[LONDON] DNA-sequencing company Oxford Nanopore Technologies rose as much as 32 per cent as it start","content":"<p>[LONDON] DNA-sequencing company Oxford Nanopore Technologies rose as much as 32 per cent as it started trading in London, buoyed by a pandemic boost and strong demand for fast-growing tech stocks in the UK.</p>\n<p>The stock climbed 28 per cent to 545.50 pence at 8.12am from the initial public offering price of 425 pence. The IPO valued Oxford Nanopore at £3.4 billion (S$6.22 billion).</p>\n<p>Oxford Nanopore raised £350 million selling new stock, while its backers offloaded existing shares worth £174 million, according to a statement Thursday.</p>\n<p>The shares were priced in the the top half of the range at which they were marketed. The University of Oxford spinoff's holders sold more shares in the IPO than planned due to high demand.</p>\n<p>The Oracle-backed company provides Covid-19 test kits to Britain's National Health Service, and its sequencing technology has been used by researchers to characterise the genome of the Sars-CoV-2 virus to identify and track variants.</p>\n<p>Oxford Nanopore has added about US$1 billion to its market value since its last funding round in May, placing it among the UK's most valuable startups. The IPO is an important win for London's ambitions to boost its profile as a hub for innovative businesses.</p>\n<p>The company has also given Gordon Sanghera, its founder and chief executive officer, a special class of shares with extra power to block an unwanted takeover. Though panned by some investors for diluting voting rights, there are plans to allow multiple classes of shares on the London Stock Exchange's top-tier premium market.</p>\n<p>For now, Oxford Nanopore is relegated to the bourse's standard segment, which means it is ineligible for certain major benchmarks like the FTSE Russell indices.</p>\n<p>Bank of America, Citigroup and JPMorgan Chase & Co are global coordinators of the offering. Barclays Bank, Berenberg, Guggenheim Securities, Numis Corp and RBC Capital Markets are joint bookrunners.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Temasek-backed Covid-19 test provider Oxford Nanopore soars in London trading debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTemasek-backed Covid-19 test provider Oxford Nanopore soars in London trading debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-30 16:18 GMT+8 <a href=https://www.businesstimes.com.sg/garage/temasek-backed-covid-19-test-provider-oxford-nanopore-soars-in-london-trading-debut><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>[LONDON] DNA-sequencing company Oxford Nanopore Technologies rose as much as 32 per cent as it started trading in London, buoyed by a pandemic boost and strong demand for fast-growing tech stocks in ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/garage/temasek-backed-covid-19-test-provider-oxford-nanopore-soars-in-london-trading-debut\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.businesstimes.com.sg/garage/temasek-backed-covid-19-test-provider-oxford-nanopore-soars-in-london-trading-debut","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104048333","content_text":"[LONDON] DNA-sequencing company Oxford Nanopore Technologies rose as much as 32 per cent as it started trading in London, buoyed by a pandemic boost and strong demand for fast-growing tech stocks in the UK.\nThe stock climbed 28 per cent to 545.50 pence at 8.12am from the initial public offering price of 425 pence. The IPO valued Oxford Nanopore at £3.4 billion (S$6.22 billion).\nOxford Nanopore raised £350 million selling new stock, while its backers offloaded existing shares worth £174 million, according to a statement Thursday.\nThe shares were priced in the the top half of the range at which they were marketed. The University of Oxford spinoff's holders sold more shares in the IPO than planned due to high demand.\nThe Oracle-backed company provides Covid-19 test kits to Britain's National Health Service, and its sequencing technology has been used by researchers to characterise the genome of the Sars-CoV-2 virus to identify and track variants.\nOxford Nanopore has added about US$1 billion to its market value since its last funding round in May, placing it among the UK's most valuable startups. The IPO is an important win for London's ambitions to boost its profile as a hub for innovative businesses.\nThe company has also given Gordon Sanghera, its founder and chief executive officer, a special class of shares with extra power to block an unwanted takeover. Though panned by some investors for diluting voting rights, there are plans to allow multiple classes of shares on the London Stock Exchange's top-tier premium market.\nFor now, Oxford Nanopore is relegated to the bourse's standard segment, which means it is ineligible for certain major benchmarks like the FTSE Russell indices.\nBank of America, Citigroup and JPMorgan Chase & Co are global coordinators of the offering. Barclays Bank, Berenberg, Guggenheim Securities, Numis Corp and RBC Capital Markets are joint bookrunners.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/865258718"}
精彩评论